

AIPPEAR: AUTOIMMUNE PANCREATITIS, PANCREATIC AND EXTRAPANCREATIC CANCER – A RETROSPECTIVE GLOBAL MULTICENTER STUDY

Cecilie Siggaard Knoph

UEG Week Berlin 2025

Poster

Pancreas

October 4, 2025

A global multicenter retrospective observational study is investigating cancer incidence in autoimmune pancreatitis patients, addressing a gap in reliable data on malignancy risk in this rare condition.

KEY POINTS

- The study collects data from patients with autoimmune pancreatitis diagnosed after 2005, including type 1, type 2, and not-otherwise-specified subtypes, with at least 12 months of follow-up.
- The primary outcome is the occurrence of first invasive cancer after autoimmune pancreatitis diagnosis, with standardized incidence ratios compared to age-grouped and gender-matched controls from the general population using the Cancer Incidence in Five Continents Volume XI registry.
- Secondary outcomes include characteristics of patients who develop pancreatic or extrapancreatic cancers and the prevalence of cancer diagnoses within 12 months prior to autoimmune pancreatitis diagnosis.
- Recruitment status shows 321 cases entered from 16 centers in Europe and America, with ethics submissions applied for in an additional 45 centers across four continents.
- The authors state this is the first global observational trial analyzing cancer risk in autoimmune pancreatitis patients, to their knowledge.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/d9d40eb8-a813-11f0-97f4-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.